Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Technospiron is a monophasic combined oral contraceptive pill (COCP) containing 0.03 mg of ethinyl estradiol and 3 mg of drospirenone. Ethinyl estradiol is a synthetic estrogen that suppresses follicle-stimulating hormone (FSH) and provides endometrial stability, while drospirenone is a fourth-generation progestin that inhibits ovulation by suppressing luteinizing hormone (LH). Drospirenone is chemically related to spironolactone and possesses unique anti-mineralocorticoid and anti-androgenic properties, which help minimize estrogen-related water retention and androgenic side effects like acne. In clinical research conducted by Benha University, Technospiron was evaluated for its efficacy in managing symptomatic abnormal uterine bleeding (AUB) specifically related to a uterine niche (cesarean scar defect), where it works by thinning the endometrial lining and regulating the menstrual cycle to reduce niche-related spotting and heavy bleeding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Technospiron.